Quest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA®
Quest Diagnostics announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx™ immunohistochemistry companion diagnostic. The FDA has approved Merck's KEYTRUDA® (pembrolizumab) for treatment of patients with metastatic NSCLC. October 02, 2015